NCT03032107 is a phase Ib clinical trial focusing on the effects of the combination treatment of T-DM1 and pembrolizumab in metastatic HER2-positive breast cancer patients who have previously been treated with taxane, trastuzumab, and pertuzumab but have not experienced T-DM1. This evidence concerns the gene ERBB2 and breast carcinoma.